Lupin's prophylaxis and chronic asthma treatment drug gets USFDA nod

Topics Lupin Pharma | USFDA | Asthma


Domestic pharma firm Lupin on Friday said it has received approval from the US health regulator for its generic Zileuton extended-release tablets used as prophylaxis and in treatment of chronic asthma.

The approval by the US Food and Drug Administration (USFDA) is for Zileuton extended-release tablets of strength 600 mg, which is the generic equivalent of Zyflo CR of Chiesi USA, Inc, Lupin said in a regulatory filing.

The medicine is indicated for prophylaxis and treatment of chronic asthma in adults and children 12 years of age and older, it added.

Citing IQVIA MAT September 2019 data, the company said Zileuton extended-release tablets, 600 mg had annual sales of approximately $43 million in the US.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel